A Novel Diabetes Mellitus Mouse Model, MAFA-Deficient and Beta Cell-Specific MAFK-Overexpressing Hybrid Transgenic Mice, Developed Severe Diabetic Nephropathy and Improved with TCV-116 (Candesartan Cilexetil) Treatment

Experimental Animals

Volumn 61, Issue 1, 2012, Pages 49-57

  Fujita, Akiko ^a   Yoh, Keigyou ^a   Shimohata, Homare ^b   Morito, Naoki ^a   Ojima, Masami ^a   Okamura, Midori ^a   Takahashi, Satoru ^a   Yamagata, Kunihiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti angiotensin II receptor blockers; Diabetic nephropathy model mouse; Renin angiotensin system

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CANDESARTAN HEXETIL; CREATININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; EXPERIMENTAL MOUSE; GLOMERULAR STRUCTURE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY HYPERTROPHY; KIDNEY SIZE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN SECRETION; PROTEIN URINE LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSGENIC MOUSE; TREATMENT DURATION; UNINEPHRECTOMY;

MUS; MUS MUSCULUS;

EID: 84856601382     PISSN: 13411357     EISSN: None     Source Type: Journal    
DOI: 10.1538/expanim.61.49     Document Type: Article

References (35)

1. Anan, F., Takahashi, N., Ooie, T., Hara, M., Yoshimatsu, H., and Saikawa, T. 2004. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 53: 777-781.
2. Benkhelifa, S., Provot, S., Lecoq, O., Pouponnot, C., Calothy, G., and Felder-Schmittbuhl, M.P. 1998. MafA, a novel member of the maf proto-oncogene family, displays developmental regulation and mitogenic capacity in avian neuroretina cells. Oncogene 17: 247-254.
3. Brewster, U.C. and Perazella, M.A. 2004. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 116: 263-272.
4. Breyer, M.D., Bottinger, E., Brosius, F.C. 3rd, Coffman, T.M., Harris, R.C., Heilig, C.W., and Sharma, K. 2005. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16: 27-45.
5. Ceriello, A. 2003. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26: 1589-1596.
6. Chabrashvili, T., Kitiyakara, C., Blau, J., Karber, A., Aslam, S., Welch, W.J., and Wilcox, C.S. 2003. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285: R117-124.
7. Chawla, T., Sharma, D., and Singh, A. 2010. Role of the renin angiotensin system in diabetic nephropathy. World J. Diabetes 1: 141-145.
8. 2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 50: 2114-2125.
9. Fujiwara, K.T., Kataoka, K., and Nishizawa, M. 1993. Two new members of the maf oncogene family, mafK and mafF, encode nuclear b-Zip proteins lacking putative trans-activator domain. Oncogene 8: 2371-2380.
10. Kajihara, M., Sone, H., Amemiya, M., Katoh, Y., Isogai, M., Shimano, H., Yamada, N., and Takahashi, S. 2003. Mouse MafA, homologue of zebrafish somite Maf 1, contributes to the specific transcriptional activity through the insulin promoter. Biochem. Biophys. Res. Commun. 312: 831-842.
11. Kataoka, K., Han, S.I., Shioda, S., Hirai, M., Nishizawa, M., and Handa, H. 2002. MafA is a glucose-regulated and pancreatic beta-cell-specific transcriptional activator for the insulin gene. J. Biol. Chem. 277: 49903-49910.
12. Kataoka, K., Shioda, S., Ando, K., Sakagami, K., Handa, H., and Yasuda, K. 2004. Differentially expressed Maf family transcription factors, c-Maf and MafA, activate glucagon and insulin gene expression in pancreatic islet alpha-and beta-cells. J. Mol. Endocrinol. 32: 9-20.
13. King, G.L. and Loeken, M.R. 2004. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem. Cell Biol. 122: 333-338.
14. Koya, D., Lee, I.K., Ishii, H., Kanoh, H., and King, G.L. 1997. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J. Am. Soc. Nephrol. 8: 426-435.
15. Leiter, E.H. 1982. Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus. Proc. Natl. Acad. Sci. U.S.A. 79: 630-634.
16. Mathews, C.E., Langley, S.H., and Leiter, E.H. 2002. New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation 73: 1333-1336.
17. Matsuoka, T.A., Zhao, L., Artner, I., Jarrett, H.W., Friedman, D., Means, A., and Stein, R. 2003. Members of the large Maf transcription family regulate insulin gene transcription in islet beta cells. Mol. Cell. Biol. 23: 6049-6062.
18. Mogensen, C.E. and Andersen, M.J. 1975. Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment. Diabetologia 11: 221-224.
19. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M.A., Beebe, D., Oates, P.J., Hammes, H.P., Giardino, I., and Brownlee, M. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790.
20. Noda, M., Matsuo, T., Fukuda, R., Ohta, M., Nagano, H., Shibouta, Y., Naka, T., Nishikawa, K., and Imura, Y. 1999. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int. 56: 898-909.
21. Olbrot, M., Rud, J., Moss, L.G., and Sharma, A. 2002. Identification of beta-cell-specific insulin gene transcription factor RIPE3b1 as mammalian MafA. Proc. Natl. Acad. Sci. U.S.A. 99: 6737-6742.
22. Padi, S.S. and Chopra, K. 2002. Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol. Res. 45: 413-420.
23. Ritz, E. 2007. Prevention and treatment of diabetic nephropathy. pp. 365-373. In: Comprehensive Clinical Nephrology, 3rd ed. (Feehally, J., Floege, J., and Johnson, R.J. eds.), Elsevier, PA.
24. Ruggenenti, P., Cravedi, P., and Remuzzi, G. 2010. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat. Rev. Nephrol. 6: 319-330.
25. Shao, J., Iwashita, N., Ikeda, F., Ogihara, T., Uchida, T., Shimizu, T., Uchino, H., Hirose, T., Kawamori, R., and Watada, H. 2006. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem. Biophys. Res. Commun. 344: 1224-1233.
26. Sharma, K., McCue, P., and Dunn, S.R. 2003. Diabetic kidney disease in the db/db mouse. Am. J. Physiol. Renal. Physiol. 284: F1138-1144.
27. Shimohata, H., Yoh, K., Fujita, A., Morito, N., Ojima, M., Tanaka, H., Hirayama, K., Kobayashi, M., Kudo, T., Yamagata, K., and Takahashi, S. 2009. MafA-deficient and beta cell-specific MafK-overexpressing hybrid transgenic mice develop human-like severe diabetic nephropathy. Biochem. Biophys. Res. Commun. 389: 235-240.
28. Shimohata, H., Yoh, K., Morito, N., Shimano, H., Kudo, T., and Takahashi, S. 2006. MafK overexpression in pancreatic beta-cells caused impairment of glucose-stimulated insulin secretion. Biochem. Biophys. Res. Commun. 346: 671-680.
29. Taal, M.W. and Brenner, B.M. 2000. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 57: 1803-1817.
30. Tesch, G.H. and Nikolic-Paterson, D.J. 2006. Recent insights into experimental mouse models of diabetic nephropathy. Nephron Exp. Nephrol. 104: e57-62.
31. Velasquez, M.T., Kimmel, P.L., and Michaelis, O.E. 4th. 1990. Animal models of spontaneous diabetic kidney disease. FASEB J. 4: 2850-2859.
32. Watanabe, Y., Itoh, Y., Yoshida, F., Koh, N., Tamai, H., Fukatsu, A., Matsuo, S., Hotta, N., and Sakamoto, N. 1991. Unique glomerular lesion with spontaneous lipid deposition in glomerular capillary lumina in the NON strain of mice. Nephron 58: 210-218.
33. Wiernsperger, N.F. 2003. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab. 29: 579-585.
34. Zatz, R., Dunn, B.R., Meyer, T.W., Anderson, S., Rennke, H.G., and Brenner, B.M. 1986. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77: 1925-1930.
35. Zhang, C., Moriguchi, T., Kajihara, M., Esaki, R., Harada, A., Shimohata, H., Oishi, H., Hamada, M., Morito, N., Hasegawa, K., Kudo, T., Engel, J.D., Yamamoto, M., and Takahashi, S. 2005. MafA is a key regulator of glucose-stimulated insulin secretion. Mol. Cell. Biol. 25: 4969-4976.